Paper28291388
Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels.
Kochenderfer JN and 21 others. J Clin Oncol, 2017. Cited by 487 papers, by iCite.
Cite this record
ConductScience Library. Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels. Papers, record 28291388. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28291388
- Disease
- B-cell chronic lymphocytic leukemia345 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels.
- PubMed
Connected records3
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Immunotherapy, Adoptive | Major topic |
| Interleukin-15 | Major topic |
| Lymphoma | Major topic |
| T-Lymphocytes | Major topic |
| Adult | |
| Aged | |
| Antigens, CD19 | |
| Cyclophosphamide | |
| Humans | |
| Middle Aged | |
| Receptors, Antigen, T-Cell | |
| Transplantation Conditioning | |
| Vidarabine |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| ZIABC011417 | NIH | NIH RePORTER | |||
| ZICBC011569 | NIH | NIH RePORTER |
Trials2
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT00924326 | CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma | Results | ClinicalTrials.gov | |
| NCT06339255 | Italian Observational Study on CAR-T Therapy for Lymphoma | Results | ClinicalTrials.gov |
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 28352132 | Immunotherapy: DLBCL remissions driven by CARs. | https://conductscience.org/library/papers/28352132 |
Source PubMed
References52
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 22952817 | Granzyme B-induced neurotoxicity is mediated via activation of PAR-1 receptor and Kv1.3 channel. | PLoS One | 2012 | https://conductscience.org/library/papers/22952817 | PubMed |
| 2 | 26325036 | CAR therapy: the CD19 paradigm. | J Clin Invest | 2015 | https://conductscience.org/library/papers/26325036 | PubMed |
| 3 | 20668228 | Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. | Blood | 2010 | https://conductscience.org/library/papers/20668228 | PubMed |
| 4 | 16203864 | Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. | J Exp Med | 2005 | https://conductscience.org/library/papers/16203864 | PubMed |
| 5 | 27605551 | Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. | Sci Transl Med | 2016 | https://conductscience.org/library/papers/27605551 | PubMed |
| 6 | 20428207 | Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. | Leukemia | 2010 | https://conductscience.org/library/papers/20428207 | PubMed |
| 7 | 27482888 | Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. | J Clin Invest | 2016 | https://conductscience.org/library/papers/27482888 | PubMed |
| 8 | 23344265 | B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. | Clin Cancer Res | 2013 | https://conductscience.org/library/papers/23344265 | PubMed |
| 9 | 17242396 | Revised response criteria for malignant lymphoma. | J Clin Oncol | 2007 | https://conductscience.org/library/papers/17242396 | PubMed |
| 10 | 25317870 | Chimeric antigen receptor T cells for sustained remissions in leukemia. | N Engl J Med | 2014 | https://conductscience.org/library/papers/25317870 | PubMed |
| 11 | 24778315 | IL-10: master switch from tumor-promoting inflammation to antitumor immunity. | Cancer Immunol Res | 2014 | https://conductscience.org/library/papers/24778315 | PubMed |
| 12 | 24553386 | Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. | Sci Transl Med | 2014 | https://conductscience.org/library/papers/24553386 | PubMed |
| 13 | 19561539 | Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. | J Immunother | 2009 | https://conductscience.org/library/papers/19561539 | PubMed |
| 14 | 26811520 | Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease. | J Clin Oncol | 2016 | https://conductscience.org/library/papers/26811520 | PubMed |
| 15 | 23375551 | Diffuse large B-cell lymphoma. | Crit Rev Oncol Hematol | 2013 | https://conductscience.org/library/papers/23375551 | PubMed |
| 16 | 6460831 | Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. | J Exp Med | 1982 | https://conductscience.org/library/papers/6460831 | PubMed |
| 17 | 22581824 | IL-10 directly activates and expands tumor-resident CD8(+) T cells without de novo infiltration from secondary lymphoid organs. | Cancer Res | 2012 | https://conductscience.org/library/papers/22581824 | PubMed |
| 18 | 26627006 | IL15 and T-cell Stemness in T-cell-Based Cancer Immunotherapy. | Cancer Res | 2015 | https://conductscience.org/library/papers/26627006 | PubMed |
| 19 | 11568001 | Interleukin-10 promotes the maintenance of antitumor CD8(+) T-cell effector function in situ. | Blood | 2001 | https://conductscience.org/library/papers/11568001 | PubMed |
| 20 | 20631379 | Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. | Blood | 2010 | https://conductscience.org/library/papers/20631379 | PubMed |
Cited by368
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 487 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42969556 | Bendamustine induces peripheral lymphodepletion in dogs with relapsed lymphoma. | J Vet Intern Med | 2026 | https://conductscience.org/library/papers/42969556 | PubMed |
| 42816506 | Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases. | Signal Transduct Target Ther | 2026 | https://conductscience.org/library/papers/42816506 | PubMed |
| 42605790 | Metabolic activation using fructose-1,6-bisphosphate microparticles of non-virally LNP-generated CAR-macrophages induces anti-tumor immune responses. | J Mater Chem B | 2026 | https://conductscience.org/library/papers/42605790 | PubMed |
| 42187436 | Machine Learning-Assisted Rapid Optical Imaging for Label-Free CAR T-Cell Detection in Whole Blood. | Biosensors (Basel) | 2026 | https://conductscience.org/library/papers/42187436 | PubMed |
| 42066750 | Distinct in vivo dynamics of donor-derived stem cell memory CAR T cells post-allogeneic HSCT relapse. | Cell | 2026 | https://conductscience.org/library/papers/42066750 | PubMed |
| 41998030 | Hematological parameters as predictive indicators of disease stage in patients with cervical cancer. | Sci Rep | 2026 | https://conductscience.org/library/papers/41998030 | PubMed |
| 41912833 | Baseline absolute lymphocyte count, C-reactive protein, and ferritin predict CAR T cell-related toxicities and outcomes in multiple myeloma. | Bone Marrow Transplant | 2026 | https://conductscience.org/library/papers/41912833 | PubMed |
| 41831087 | 6-month Progression-Free Survival (PFS6) as a prognostic factor in large B-cell lymphoma patients undergoing chimeric antigen receptor T-cell therapy: A real-world multicenter study. | Ann Hematol | 2026 | https://conductscience.org/library/papers/41831087 | PubMed |
| 41702648 | Corticosteroids ameliorate CAR T-cell-induced cytokine-release syndrome without inhibiting multiple myeloma treatment. | J Immunother Cancer | 2026 | https://conductscience.org/library/papers/41702648 | PubMed |
| 41686452 | Ibrutinib exposure correlates with improved efficacy of CAR T cells in patients with mantle cell lymphoma. | Blood Adv | 2026 | https://conductscience.org/library/papers/41686452 | PubMed |
| 41591467 | Unleashing CAR-T potential in solid tumors: overcoming intrinsic and extrinsic hurdles to improve therapy. | Cancer Immunol Immunother | 2026 | https://conductscience.org/library/papers/41591467 | PubMed |
| 41559435 | CAR-engineered cell therapies: current understandings and future perspectives. | Mol Biomed | 2026 | https://conductscience.org/library/papers/41559435 | PubMed |
| 41516067 | Pre-Treatment with Dacarbazine Sensitizes B16 Melanoma to CAR T Cell Therapy in Syngeneic Mouse Model. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41516067 | PubMed |
| 41507382 | Can modified lymphodepletion before tisagenlecleucel improve outcome in high-risk patients with large B-cell lymphoma? | Bone Marrow Transplant | 2026 | https://conductscience.org/library/papers/41507382 | PubMed |
| 41492094 | Axicabtagene ciloleucel in combination with rituximab for refractory large B cell lymphoma: the phase 2, single-arm ZUMA-14 trial. | Nat Cancer | 2026 | https://conductscience.org/library/papers/41492094 | PubMed |
| 41324276 | The Pleiotropic Roles of Cytokines in Chimeric Antigen Receptor T-cell Therapy. | Cancer Immunol Res | 2026 | https://conductscience.org/library/papers/41324276 | PubMed |
| 41306534 | Case Report: Rare adverse events following CAR-T therapy in patients with relapsed/refractory diffuse large B-cell lymphoma. | Front Oncol | 2025 | https://conductscience.org/library/papers/41306534 | PubMed |
| 41024300 | Transforming cancer immunotherapy: integration of distinct immune-based approaches as redefined dual immunotherapy with potential third-sensitizer. | Exp Hematol Oncol | 2025 | https://conductscience.org/library/papers/41024300 | PubMed |
| 40873568 | CAR T-cell therapy in autoimmune diseases: a promising frontier on the horizon. | Front Immunol | 2025 | https://conductscience.org/library/papers/40873568 | PubMed |
| 40847431 | Revolutionizing cardiac fibrosis treatment: the potential of personalized CAR T-cell therapy. | Cardiooncology | 2025 | https://conductscience.org/library/papers/40847431 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD19 | 930 | PubTator's text mining | https://conductscience.org/library/genes/930 | NCBI Gene |
| CXADRP1 | 653108 | PubTator's text mining | https://conductscience.org/library/genes/653108 | NCBI Gene |
| IL15 | 3600 | PubTator's text mining | https://conductscience.org/library/genes/3600 | NCBI Gene |
Drugs3
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| CYCLOPHOSPHAMIDE | CHEMBL1200796 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL1200796 | ChEMBL |
| ALDESLEUKIN | CHEMBL1201438 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL1201438 | ChEMBL |
| FLUDARABINE | CHEMBL1568 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL1568 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28291388
GET https://conductscience.org/api/papers/v1/28291388/authors?page=2